❓What are the outcomes of checkpoint inhibitors after progression to TIL therapy in #melanoma? 👇Check the work led by the brilliant James Smithy of @MSKCancerCenter with multiple international groups including our team at @CCITdk

🔵 Just published in @JNCI_Now: pCR and ctDNA clearance prognostic dynamics after neoadjuvant/perioperative IO Pan-tumor reconstructed IPD analysis | 1,867 pCR + 352 ctDNA-clearance patients | 8 tumor types -3-yr EFS after pCR ranges from 78.6% (#NSCLC) to 100% (dMMR-#CRC) -No EFS benefit from postoperative adjuvant IO in patients achieving pCR (cross-trial) -#ctDNA clearance shows heterogeneous prognostic value 📢A call towards an individualized neo/periop treatment 🔗academic.oup.com/jnci/advanc… 🧙‍♂️👉 @DoniaMarco, @ProfCUBlankNKI, @MARIANOPROVENCI & @ChristianRolfo #Immunotherapy

🔵 Our new paper in @JNCI_Now: do reimbursed drugs deliver in routine care what trials promised? A new framework quantifies the efficacy-effectiveness gap from a national registry (🇩🇰,DAMMED). In #melanoma: - IO deviated only in ineligible pts (HR 1.61) - Targeted therapy deviated even in eligible ones 🔍The method is exportable to any registry-backed disease. 🧙‍♂️ Senior and corresponding 👉@DoniaMarco 📚Full paper 👇👇👇

How well do #melanoma trial results predict routine-care outcomes? 👉In first-line metastatic melanoma it turns on two things: trial eligibility and drug class. New @JNCI_Now paper. 🇩🇰Danish registry, 1909 patients, vs reconstructed trial data. 🧵 doi.org/10.1093/jnci/djag196

All complete responses to immunotherapy are created equal: across tumour types, not across response depth. Two papers from @CCITdk , two methods, one conclusion. 🧵

📣 Our new paper in @JNCCN: acquired resistance to #immunotherapy (ARI) across 11 tumor types Reconstructed IPD: 15,199 pts / 41 phase 3 trials • 73.5% develop ARI by 3y • Higher CR/PR → less ARI, regardless of tumor type ARI may be determined by response depth, not histology Cheers to @DoniaMarco & @CCITdk 🇩🇰 Full paper 👇👇👇

📣 New in #EJC: among PD-(L)1 responders, durability tracks response depth, not tumor type Our nationwide cohort 🇩🇰: 2,127 responders (#melanoma, #RCC, #NSCLC) • Within CR & within PR, PFS near-identical across tumors • PR vs CR = dominant factor Two papers, two faces of the same coin 🪙: response depth, not tumor type, drives the risk of acquired resistance to IO Trial-level (@JNCCN) + real-world (#EJC), same conclusion Cheers to @DoniaMarco & @CCITdk Full paper 👇👇 #LCSM #IO

🎥 @holmstrom_mo of @CCITdk shares outcomes from a study investigating immune reconstitution in patients with #Myelofibrosis conditioned with a non-myeloablative regimen prior to alloSCT: ➡️ ow.ly/9zC550YXw7F #MPNsm #BMTsm #HemOnc #ESHMPN2026

In a recent interview, @holmstrom_mo of @CCITdk discussed the potential of therapeutic cancer vaccines in MPNs, highlighting the challenges of integrating vaccine strategies into treatment. 💉🩸 Click here to watch the full interview: 🎥 👉 ow.ly/cBWP50YXv1I #ESHMPN2026 #MPNsm #ImmunoOnc #HemOnc

🆕 Nationwide real-world (DAMMED 🇩🇰) study comparing Dab/Tram vs Enco/Bini in 751 pts with BRAFm metastatic melanoma. ⚖️ No differences in efficacy 🧩 Consistent across subgroups (incl. 🧠 mets) 📄 doi.org/10.1093/jnci/djaf263 In @JNCI_Now @CCITdk @DoniaMarco #Melanoma #Oncology

@CCITdk is happy to support the candidacy of Professor @ulassen to this important post at ESMO @myESMO

Acquired resistance to Cancer Immunotherapy Free at bit.ly/4jptfZz ➡️ Metastatic cancers can be cured ➡️ Pts who initially respond can develop resistance (up to 65% of responders) ❗One of the top priorities in Oncology Reviewed in @TrendsMolecMed @CCITdk @MdCurioni

New #JITC article: Arginase-1-specific T cells target and modulate tumor-associated macrophages bit.ly/3PZKkMP @marper2323 @CCITdk

🎉Cell Therapy Milestone 👍This week, a patient with melanoma received the first non-viral CRISPR-edited TIL infusion product at @CCITdk Congrats to Cell Therapy team @ozcan_met: from preclinical pubmed.ncbi.nlm.nih.gov/3514… to GMP grade clinicaltrials.gov/study/NCT…

📢 Check out this special case report by Monberg, Svane & colleagues @CCITdk @helsinkiuni @Rigshospitalet 🇩🇰🇫🇮. 💉Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Available #OpenAccess 👇esmoiotech.org/article/S2590…

📣 PhD course "Cancer Immunology and Immunotherapy", 4th edition 📃 Course Description and registration 👉bit.ly/40vh1YI ▶WHEN: 07-11/04/2025 (mon-fri) ▶WHERE: Copenhagen Area, Denmark 📩 Full program available soon! Previous edition at bit.ly/3CoqXcB

📢The Copenhagen Symposium on T Cell Therapy and Cellular Engineering (CATC) 2024 ⏰ 24-25 September 2024 📍 Greater Copenhagen, Denmark More at catc.dtu.dk/about

New publication on #MPNsm from @CCITdk published in @BrJHaem: Peripheral blood lymphocytes (PBL) from patients with CALR mutant #MPNsm display increased levels of surface TGFb and GARP. Probably mediated by enhanced binding of activated platelets to PBL. doi.org/10.1111/bjh.19711

📣 Webinar "Adoptive cell immunotherapies for cancer" SN Oncology Webinar Series on 14 May at 4 pm CEST by @SpringerNature 👉 Free registration at: cassyni.com/events/Y5qVZUYYn… 👩‍🔬 Speaker: Inge Marie Svane, Director of @CCITdk 👨‍🎓 Chair: Luca Danelli, Senior Editor @NatureComms

💬 Fantastic keynote lecture by Dr. Inge Marie Svane from @CCITdk on TIL therapies at VHIO under the framework of #PragamTIL Annual Meeting.